Aligos Therapeutics (ALGS)
(Delayed Data from NSDQ)
$8.04 USD
+0.13 (1.64%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $7.93 -0.11 (-1.37%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Aligos Therapeutics, Inc. has a market cap of $48.36M, which represents its share price of $7.91 multiplied by its outstanding shares number of 6.11M. As a small-cap company, ALGS's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ALGS 8.04 +0.13(1.64%)
Will ALGS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALGS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALGS
Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates
ALGS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates
UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
Other News for ALGS
Aligos Therapeutics GAAP EPS of -$1.53 beats by $0.83
Aligos Therapeutics Inc Q2 2025 Earnings: EPS of $(1. ...
Aligos Therapeutics reports Q2 EPS ($1.53), consensus ($2.54)
Earnings Scheduled For August 6, 2025
Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025 | ALGS ...